RxDoctor Payments Data

Karina Arocho-Gonzalez

Hematology & Oncology · Hato Rey, PRNPI 1851724512

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,212 of the $10,674 with a category attached, or 76.9%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $2,844 and has fallen 59.0% since, to $1,167 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PR, where the typical reported total is $10,882.

$10,674in general payments, 2019–2025

Across 345 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$2K
  • Johnson & Johnson$1K
  • E.r. Squibb & Sons, L.L.C.$678
  • Genentech USA, Inc.$673
  • Amgen$665
  • PBG Puerto Rico LLC$655
  • plus $5K from 33 others
$1,124,310in research payments, 2019–2025

Across 84 payments — averaging $13,385 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$909K
  • Pfizer$107K
  • Beone Medicines Ltd.$45K
  • Janssen Research & Development, LLC$35K
  • AstraZeneca$25K
  • Jazz Pharmaceuticals Inc.$4K

What the payments were for

  • Consulting fees$2,25021%
  • Food & beverage$8,21277%
  • Education$2122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,674 in reported general payments places this provider in the 45th percentile of 138 hematology & oncology providers in Puerto Rico.

See all hematology & oncology providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine41$529,592
RevlimidLenalidomide21$340,678
TagrissoOsimertinib Mesylate13$214,230
ErleadaApalutamide13$192,962
AvastinBevacizumab12$47,816
Abiraterone Acetate17$30,944
RetacritEpoetin Alfa-Epbx16$12,752
Hydroxyurea40$1,034
Anastrozole62$1,003
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$495
Tamoxifen Citrate14$351
Ondansetron Hcl21$293
Dexamethasone21$173
Prednisone21$132
Pantoprazole Sodium12$124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta$362$529,59241 claims
Bristol Myers SquibbRevlimid$30$340,67821 claims
AstraZenecaTagrisso$611$214,23013 claims
Johnson & JohnsonErleada$1,093$192,96213 claims
PfizerRetacrit$113$12,75216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 138 hematology & oncology providers in Puerto Rico.

Other hematology & oncology in Hato Rey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →